What is he best known for?
The fields of study he is best known for:
- Cancer
- Gene
- Internal medicine
François Ghiringhelli mainly focuses on Immune system, Cancer research, Immunology, Immunogenic cell death and Cell biology.
His Immune system research includes themes of Cancer cell, Chemotherapy, Programmed cell death and Antigen.
His research in Cancer research intersects with topics in Cell culture, Cisplatin, CD8 and Cytotoxic T cell, Adoptive cell transfer.
His Immunology study integrates concerns from other disciplines, such as Cancer, Radiation therapy and Myeloid-derived Suppressor Cell.
His Immunogenic cell death research is multidisciplinary, incorporating elements of Toll-like receptor and Oxaliplatin.
His Cell biology research includes elements of Interleukin 3, Interleukin 21, Cell, Transcription factor and Interleukin 12.
His most cited work include:
- Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. (2103 citations)
- Calreticulin exposure dictates the immunogenicity of cancer cell death (1856 citations)
- Calreticulin exposure dictates the immunogenicity of cancer cell death (1856 citations)
What are the main themes of his work throughout his whole career to date?
Internal medicine, Oncology, Cancer research, Immune system and Colorectal cancer are his primary areas of study.
Internal medicine and Gastroenterology are frequently intertwined in his study.
The study incorporates disciplines such as Phases of clinical research, Surgery, FOLFIRINOX and Breast cancer in addition to Oncology.
His Cancer research course of study focuses on Cell and Calreticulin.
His Immune system research is multidisciplinary, incorporating elements of Cancer cell, Cancer and Cytotoxic T cell.
The various areas that François Ghiringhelli examines in his Cancer cell study include Programmed cell death and Cell biology.
He most often published in these fields:
- Internal medicine (42.13%)
- Oncology (33.33%)
- Cancer research (37.04%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (42.13%)
- Oncology (33.33%)
- Cancer research (37.04%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Internal medicine, Oncology, Cancer research, Colorectal cancer and Immune system.
His Internal medicine study which covers Gastroenterology that intersects with Neutropenia.
His work in Oncology addresses issues such as Regimen, which are connected to fields such as Docetaxel.
His study in Cancer research is interdisciplinary in nature, drawing from both Immune checkpoint, Cancer, Immunogenic cell death, Immunotherapy and Immunity.
His Colorectal cancer research is multidisciplinary, relying on both Aflibercept and MAPK/ERK pathway.
His research in Immune system focuses on subjects like Transcription factor, which are connected to Cell biology.
Between 2017 and 2021, his most popular works were:
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors (1593 citations)
- Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial. (137 citations)
- PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer. (84 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Gene
- Internal medicine
François Ghiringhelli focuses on Internal medicine, Colorectal cancer, Cancer research, Oncology and Immune system.
He has included themes like Adjuvant, Clinical endpoint, Chemotherapy and FOXP3 in his Colorectal cancer study.
His Cancer research study combines topics in areas such as Cell culture, Psychological repression, Immunogenic cell death, Immunotherapy and Cytotoxic T cell.
He focuses mostly in the field of Immunotherapy, narrowing it down to matters related to Blockade and, in some cases, Antibody and Immunology.
In his study, which falls under the umbrella issue of Oncology, Cyclophosphamide, GiST, Metronomic Chemotherapy and Sarcoma is strongly linked to Phases of clinical research.
The Immune system study combines topics in areas such as Cancer, Tumor progression and STAT3.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
